BridgeBio Oncology Therapeutics, Inc. (BBOT) - Total Liabilities
Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has total liabilities worth $45.37 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BridgeBio Oncology Therapeutics, Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See BridgeBio Oncology Therapeutics, Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
BridgeBio Oncology Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
USA | $54.25 Million |
|
Linkage Software Co Ltd
SHG:688588
|
China | CN¥501.16 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$22.86 Million |
|
Shandong Rike Chemical
SHE:300214
|
China | CN¥2.53 Billion |
|
Gladstone Commercial Corporation
NASDAQ:GOOD
|
USA | $1.07 Billion |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
China | CN¥3.61 Billion |
|
Beijing StarNeto Technology Co Ltd
SHE:002829
|
China | CN¥573.58 Million |
|
Jinneng Science&Tech Co Ltd
SHG:603113
|
China | CN¥12.42 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down BridgeBio Oncology Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BridgeBio Oncology Therapeutics, Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BridgeBio Oncology Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BridgeBio Oncology Therapeutics, Inc. (2021–2025)
The table below shows the annual total liabilities of BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $37.28 Million | +553.26% |
| 2024-12-31 | $5.71 Million | +1339.61% |
| 2023-12-31 | $396.46K | +138.18% |
| 2022-12-31 | $166.46K | +2.35% |
| 2021-12-31 | $162.64K | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more